289 related articles for article (PubMed ID: 20615394)
1. Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy.
Cerella C; Sobolewski C; Dicato M; Diederich M
Biochem Pharmacol; 2010 Dec; 80(12):1801-15. PubMed ID: 20615394
[TBL] [Abstract][Full Text] [Related]
2. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
Chun KS; Surh YJ
Biochem Pharmacol; 2004 Sep; 68(6):1089-100. PubMed ID: 15313405
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
Grösch S; Maier TJ; Schiffmann S; Geisslinger G
J Natl Cancer Inst; 2006 Jun; 98(11):736-47. PubMed ID: 16757698
[TBL] [Abstract][Full Text] [Related]
4. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
Kashfi K; Rigas B
Biochem Pharmacol; 2005 Oct; 70(7):969-86. PubMed ID: 15949789
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation of cyclo-oxygenase expression: three pillars of control.
Ramsay RG; Ciznadija D; Vanevski M; Mantamadiotis T
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):59-67. PubMed ID: 14552705
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung.
Harris RE
Inflammopharmacology; 2009 Apr; 17(2):55-67. PubMed ID: 19340409
[TBL] [Abstract][Full Text] [Related]
7. Cancer prevention: a new era beyond cyclooxygenase-2.
Rigas B; Kashfi K
J Pharmacol Exp Ther; 2005 Jul; 314(1):1-8. PubMed ID: 15805430
[TBL] [Abstract][Full Text] [Related]
8. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis.
Peng G; Dixon DA; Muga SJ; Smith TJ; Wargovich MJ
Mol Carcinog; 2006 May; 45(5):309-19. PubMed ID: 16508969
[TBL] [Abstract][Full Text] [Related]
9. Changes in gene expression contribute to cancer prevention by COX inhibitors.
Baek SJ; Eling TE
Prog Lipid Res; 2006 Jan; 45(1):1-16. PubMed ID: 16337272
[TBL] [Abstract][Full Text] [Related]
10. Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention.
Neergheen VS; Bahorun T; Taylor EW; Jen LS; Aruoma OI
Toxicology; 2010 Dec; 278(2):229-41. PubMed ID: 19850100
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms.
Deasy BM; O'Sullivan-Coyne G; O'Donovan TR; McKenna SL; O'Sullivan GC
Cancer Lett; 2007 Oct; 256(2):246-58. PubMed ID: 17707579
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
Kismet K; Akay MT; Abbasoglu O; Ercan A
Cancer Detect Prev; 2004; 28(2):127-42. PubMed ID: 15068837
[TBL] [Abstract][Full Text] [Related]
13. COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
Nasir A; Fernandez PM; Chughtai OR; Kaiser HE
In Vivo; 2002; 16(6):501-9. PubMed ID: 12494894
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention.
Dannenberg AJ; Lippman SM; Mann JR; Subbaramaiah K; DuBois RN
J Clin Oncol; 2005 Jan; 23(2):254-66. PubMed ID: 15637389
[TBL] [Abstract][Full Text] [Related]
15. Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells.
Chan MW; Wong CY; Cheng AS; Chan VY; Chan KK; To KF; Chan FK; Sung JJ; Leung WK
Oncol Rep; 2007 Dec; 18(6):1557-62. PubMed ID: 17982644
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?
Sanborn R; Blanke CD
Semin Oncol; 2005 Feb; 32(1):69-75. PubMed ID: 15726508
[TBL] [Abstract][Full Text] [Related]
18. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
Konturek PC; Kania J; Burnat G; Hahn EG
J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():15-24. PubMed ID: 17244951
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 as a target for anticancer drug development.
Méric JB; Rottey S; Olaussen K; Soria JC; Khayat D; Rixe O; Spano JP
Crit Rev Oncol Hematol; 2006 Jul; 59(1):51-64. PubMed ID: 16531064
[TBL] [Abstract][Full Text] [Related]
20. Natural products for chemopreventive and adjunctive therapy in oncologic disease.
Dennis T; Fanous M; Mousa S
Nutr Cancer; 2009; 61(5):587-97. PubMed ID: 19838932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
